7
7
p
h
a
r
ma
c
o
lo
g
ic
e
ffe
c
t
s
,
1
9
0
4–
1
9
0
5
r
e
p
la
c
e
me
nt
th
e
r
a
p
y
,
1
9
1
0
,
1
9
1
4
,
1
9
2
1
N
i
c
o
t
i
n
e
g
u
m
,
fo
r
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
,
1
9
1
1
–
1
9
1
3
t
a
dv
e
r
s
e
r
e
a
c
t
io
n
s
,
1
9
1
6
dis
a
dv
a
nt
a
g
e
s
o
f,
1
9
1
6
do
s
a
g
e
,
1
9
1
5
–
1
9
1
6
p
a
t
ie
nt
e
du
c
a
t
io
n
,
1
9
1
6
N
i
c
o
t
i
n
e
i
n
h
a
l
e
r
,
fo
r
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
,
1
9
1
1
–
1
9
1
3
t
,
1
9
1
8
–
1
9
1
9
N
i
c
o
t
i
n
e
l
o
z
e
n
g
e
,
fo
r
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
,
1
9
1
1
–
1
9
1
3
t
adverse reactions, 1916
disadvantages, 1916
dosage, 1916
patient education, 1916
Nicotine nasal spray, for smoking cessation, 1911–1913t
advantages, 1918
adverse reactions, 1918
dosage, 1918
patient education, 1918
Nicotine patch, for smoking cessation, 1911–1913t
adverse reactions, 1915
and dermatologic conditions, 1915
disadvantages of, 1915
dosage, 1915
patient education, 1915
Nifazodone, 120t
Nifedipine, 214, 339, 923, 985t, 993, 2261t
for Raynaud’s disease, 171
Nikkomycins, 1626
Nilotinib, 128, 470t, 1990, 2031
Nilutamide, for prostate cancer, 2093
Nipent (see Pentostatin)
Nipride (see Nitroprusside)
Nitazoxanide, 1706
for diarrhea by C. parvum, 1453
for giardiasis, 1704t
Nitrates, 214
for angina, 221
for cardiac syndrome X, 229
GERD and, 503t
for HF, 271
and hydralazine, 294
oral, 294
organic, 215t
Nitro-Bid IV (see Nitroglycerin)
Nitrofurantoin, 977, 1500
adverse effects of, 1494
for chronic antimicrobial therapy, 1499t
for cystitis, 1489
for UTI, 1489t
Nitroglycerin (NTG; Nitro-Bid IV; Nitro-Stat IV; Tridil), 335t, 2207t
for ACS, 242t
administration, 547
for chest pain, 340
CNS stimulants, 1883
for hypertensive emergencies, 343–344
for MI, 253
Nitroimidazoles, 1526
Nitropress (see Nitroprusside)
Nitroprusside (Nipride, Nitropress), 335–336t, 2207t
cyanide toxicity from, 341–342
doses of, 341
hemodynamic effects of, 341
for HTN and LV dysfunction, 297
for hypertensive emergency, 340–341
sodium, 341–342
thiocyanate toxicity from, 342
Nitro-Stat IV (see Nitroglycerin)
Nivolumab, 469t, 2066
Nizatidine, 977, 1216t, 2163t
H2RA, 483t, 484
NMDA (see N-methyl-D-aspartate (NMDA))
N-methyl-D-aspartate (NMDA), 1781, 1885
for Alzheimer’s disease, 2238
N,N-diethyl-m-toluamide (DEET), 1701
skin repellents (Repel Sportsmen), 1721
Non–angiotensin-converting enzyme inhibitor vasodilator therapy, 293–294
Non-aspirin NSAIDs, 491
Nondihydropyridines, 345, 605
Nonsteroidal antiinflammatory drugs (NSAIDs), 248, 460, 694, 1633, 1720, 2009
for acute gout, 909, 913
adverse effects, 1015–1016
and AIN, 645
common cold, 1661
contraindications, 1016
for critically ill patients, 1208
for drug-induced lupus, 692
for dysmenorrhea, 1014
effects on kidney, 890–891
for endometriosis, 1019
GERD and, 503t
and GI bleeding, 887
induced anaphylaxis, 694
for JIA, 901, 902, 904
and methotrexate, 892–893
for migraine headache, 1240, 1242
for OA, 867, 870–872, 870t, 871f
for PMS, 1025
for postoperative pain management, 1180
for psoriasis, 834, 842
for RA, 881–882, 887–891
and sodium content, 275
for systemic lupus erythematosus, 706–707, 712t, 713t
for tension-type headache, 1245
teratogenic effects, 973t
ulcers from, 489, 489t, 490–491, 490t
Norcuron (see Vecuronium)
Norepinephrine (NE), 265, 689t, 1733, 2207t, 2208
for cardiogenic shock, 365
for postoperative cardiac failure, 363t
for SBP, 363–364
for septic shock, 370–371
Norethindrone, 936–938t, 1021–1022
Norethindrone acetate, 1033t
Norfloxacin (Noroxin), 549, 1326t
for chronic antimicrobial therapy, 1499t
for UTI, 1489t
Norgestimate, 936–937t
Norgestrel, 936–937t
Normodyne (see Labetalol)
Noroxin (see Norfloxacin)
Nortriptyline, 1181t, 1187t, 1191 (see also Antidepressants)
for depressive disorders, 1819t, 1821t
Novamine, 794t
Novantrone (see Mitoxantrone)
Novolin N, 1087
NovoLog (see Insulin aspart)
NPH (see Neutral protamine Hagedorn (NPH))
NSAIDS (see Nonsteroidal antiinflammatory drugs (NSAIDs))
NTG (see Nitroglycerin (NTG))
Nystatin, 1624, 1624t, 1626t, 1634
p. 2309
p. 2310
O
Obinutuzumab, 469t
Ocrelizumab, 1223
Octinoxate, 849t, 852
Octisalate (octyl salicylate), 849t, 852
Octocrylene, 849t, 852
Octreotide, 502, 549, 803
administration, 555
for variceal bleeding, 513
Ocular therapies, for rhinitis, 438
Ocupress (see Carteolol)
Ofatumumab, 469t
Ofloxacin (Floxin), 942t, 1326t
Olanzapine (Zyprexa), 472t, 474t, 475–476, 1267, 1739, 1797t, 1799t, 1837, 1849t
for acute agitation, 1846
for acute mania, 1844–1845, 1845t
for anticholinergic, 1801
for BD, 1997t
for bipolar disorder, 1849t
for CINV, 473
drug interaction with smoking, 1906t
for dyslipidemia, 1804
for end-of-life care, 88
for FGAs, 1803
for hyperprolactinemia, 1803
for OCD, 1757
for schizophrenia, 1788, 1791t, 1792, 1793, 1793t
Olanzapine–fluoxetine, 1997t
for bipolar depression, 1847t, 1849t
Olanzapine pamoate, 1795t
Olaparib, 470t
Olmesartan, 127, 154t
Olodaterol, 420t, 421, 422
Olopatadine, 439t, 440t, 1165
for allergic rhinitis, 432
Olsalazine (Dipentum), 523t
for inflammatory bowel disease, 521t
Omacetaxine, 469t
Omalizumab (Xolair)
for allergic rhinitis, 435
for asthma, 400
side effects of, 400
Ombitasvir, 1688
Omega-3 fatty acids
adverse effects, 126
for ASD, 1856
clinical pearls, 126
drug interactions, 126
for dysmenorrhea, 1015
efficacy, 126
mechanism of action, 125
pharmacokinetics/pharmacodynamics, 126
place in therapy, 126
Omeprazole, 228, 483t, 1216t, 2163t
PPI, 484, 485
for preventing SRMB, 515t
Omnaris (see Ciclesonide)
Omnicef (see Cefdinir)
Omnipen (see Ampicillin)
Omtryg, 126
Ondansetron
for NVP, 975, 976, 976t
for PONV, 478t
Ondansetron (Zofran), 472t
for NVP, 975, 976, 976t
ODT, for nausea and vomiting, 91–92
for PONV, 478t
Ophthalmic therapies, for allergic rhinitis, 434
Opiates, for osteoarthritis, 2228
Opioids, 1182t, 1196t
associated with hepatic encephalopathy, 552
for breakthrough pain management, 1201
chronic, assessment of, 1196
in critically ill patients, 1211, 1212t
discontinuing, 1196–1197
for neuropathic pain, 1188
for OA, 872
risk addiction of, 1195–1196, 1195t
risk management of, 1194
side effect management, 1203, 1203t
Oprelvekin, 1972
Optipranolol (see Metipranolol)
Optivar (see Azelastine)
OPV (see Oral polio vaccine (OPV))
Oralair, for allergic rhinitis, 435t
Oral analgesics, for burn injuries, 863
Oral anticoagulation, 195t
Oral azithromycin, 463
Oral bisphosphonates, 454
Oral contraceptives
for IVF, 961–962
for migraine headache, 1237
Oral corticosteroids, 526
Oral electrolyte solutions, 2161t
Oral fluoroquinolones, 464
Oral iron preparations, 613t
Oral norfloxacin, 549
Oral polio vaccine (OPV), 1358
Orbactiv (see Oritavancin)
Oritavancin (Orbactiv)
adverse effects of, 1333t
for aerobic gram-positive cocci, 1326t
Orlistat (Xenical, Alli), 762–763
Orphenadrine citrate, 1186t
Ortho Tri-Cyclen, 829, 830, 1923
Oseltamivir (Tamiflu), 1649t
adverse effects of, 1647t
for influenza, 1415t, 1656
pharmacokinetics of, 1653t
Osmotic diuretics, 581
Ospemifene (Osphena), 1037
Osphena (see Ospemifene)
OTC products (see Over-the-counter (OTC) products)
Over-the-counter (OTC) products, 40
antisecretory drugs, 488
Oxacillin (see Nafcillin)
Oxaliplatin, 469t, 1978–1979t, 1981t, 1996
for adverse effects, 2076–2077, 2080
for colon cancer, 2073
neurotoxicity of, 1986–1987
peripheral nerve toxicity of, 1986–1987
and peripheral neuropathies, 1986–1987
Oxaprozin, 888t
Oxazepam, 1737t, 1746
Oxazolidinone, 1399
Oxcarbazepine, 942t, 1181t, 1187t, 1279t, 1281
for acute mania, 1845
for diabetes, 1145
for seizures, 1285t, 1286
Oxiconazole, 1624t
Oxybenzone, 849t, 852
Oxybutynin chloride, 2251
Oxycodone, 499, 1187t
dosage of, 1199t
Oxygen therapy, 689t, 1244, 1659
Oxymetazoline (Afrin), 434t
Oxyquinolines, 1626
Oxytocin, 988–989
administration of, 990
adverse effects, 990–991
dosage, 990
and lactation, 999
mechanism of action, 990
for postpartum hemorrhage, 997, 997t
and uterine activity, 990
P
PAAFs (see Pediatric amino acid formulations (PAAFs))
PABA (see Para-aminobenzoic acid (PABA))
P
a
c
l
i
t
a
x
e
l
(
T
a
x
o
l
)
,
2
2
6
,
4
6
9
t
,
9
4
2
t
,
1
9
7
8
–
1
9
7
9
t
,
1
9
8
1
t
,
1
9
8
2
t
,
1
9
8
7
,
1
9
9
0
fo
r
b
r
e
a
s
t
c
a
n
c
e
r
,
2
0
5
3
n
e
ur
o
t
o
x
ic
ity
o
f,
1
9
8
5
t
fo
r
N
S
C
L
C
,
2
0
6
2
t
,
2
0
6
3
t
,
2
0
6
4
t
p
e
r
ip
h
e
r
a
l
n
e
r
v
e
t
o
x
ic
ity
o
f,
1
9
8
6
P
a
d
i
m
a
t
e
O
,
8
4
9
t
,
8
5
2
P
a
l
b
o
c
i
c
l
i
b
,
4
7
0
t
P
a
l
i
fe
r
m
i
n
,
1
9
7
5
P
a
l
i
p
e
ri
d
o
n
e
(
I
n
v
e
g
a)
,
1
7
9
6
t
,
1
7
9
7
t
,
1
7
9
9
t
fo
r
hyp
e
rp
r
o
la
c
t
in
e
mia
,
1
8
0
3
fo
r
s
c
h
iz
op
hr
e
nia
,
1
7
8
8
,
1
7
9
1
t
P
a
l
i
v
i
z
u
m
a
b
a
dminis
tr
a
t
io
n
o
f,
1
6
5
8
do
s
a
g
e
o
f,
1
6
5
8
a
g
a
in
s
t
R
S
V
,
1
6
5
8
P
a
l
o
n
o
s
e
t
r
o
n
(
A
l
o
x
i
,
A
k
y
n
z
e
o
)
,
4
7
2
t
,
4
7
3
,
4
7
5
–
4
7
6
fo
r
P
O
N
V
,
4
7
8
t
P
a
m
a
b
r
o
m
,
1
0
1
5
P
a
m
i
d
r
o
n
a
t
e
,
5
8
9
t
,
5
9
0
,
2
0
3
8
,
2
2
7
7
,
2
2
7
8
P
-
a
m
i
n
o
s
a
l
i
c
yl
i
c
a
c
i
d
(
P
A
S
)
,
1
4
3
0
t
P
a
n
i
t
u
m
u
m
a
b
,
4
6
9
t
fo
r
c
o
lo
n
c
a
n
c
e
r
,
2
0
7
3
P
a
n
o
b
i
n
o
s
t
a
t
,
4
7
0
t
P
a
n
t
o
p
r
az
o
l
e
,
4
8
3
t
,
4
8
4
,
4
8
5
,
5
0
2
,
1
2
1
6
t
,
2
1
6
3
t
fo
r
p
r
e
v
e
nt
in
g
S
R
M
B
,
5
1
5
t
P
a
p
av
e
ri
n
e
,
2
2
6
6
P
a
r
a
-
a
m
i
n
o
b
e
n
z
o
i
c
a
c
i
d
(
P
A
B
A
)
,
8
4
9
,
8
4
9
t
P
a
r
a
b
e
n
,
8
2
2
t
P
a
r
a
c
e
t
a
m
o
l
(
s
e
e
A
c
e
t
a
m
i
n
o
p
h
e
n
)
P
a
r
a
p
h
e
n
yl
e
n
e
d
i
a
m
i
n
e
,
8
2
2
t
P
a
r
a
p
l
a
t
i
n
(
s
e
e
C
a
rb
o
p
l
a
t
i
n
)
P
a
ri
c
a
l
c
i
t
o
l
,
6
2
2
P
a
ri
t
a
p
r
e
v
i
r
,
1
6
8
8
P
a
rl
o
d
e
l
(
s
e
e
B
r
o
m
o
c
ri
p
t
i
n
e
)
P
a
r
o
m
o
m
y
c
i
n
p. 2
3
1
0
p. 2
3
1
1
fo
r
a
me
b
ic
id
e
s
,
1
7
0
3
t
fo
r
a
me
b
ic
liv
e
r
a
b
s
c
e
s
s
,
1
7
0
4
t
fo
r
g
ia
r
dia
s
is
,
1
7
0
4
t
P
a
r
o
x
e
t
i
n
e
(
P
a
x
i
l
)
,
5
9
,
1
0
2
7
t
,
1
7
3
8
t
,
1
7
4
8
,
1
8
1
0
fo
No comments:
Post a Comment
اكتب تعليق حول الموضوع